J&J's Janssen Reports IMBRUVICA 'Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation'
December 09, 2014 at 07:39 AM EST
Results from the Phase 2 RESONATETM-17 (PCYC-1117) study show IMBRUVICA® (ibrutinib) was associated with an 82.6 percent ...
